Fatima Smih
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fatima Smih has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Annie Turkieh
Inserm, CHU Lille, Institut Pasteur de Lille, U1167‐RID‐AGE Université de Lille Lille France
4 shared publications - Philippe Rouet
LA Maison de la MItochondrie (LAMMI), Obesity and heart failure: molecular and clinical investigations, UMR CNRS 5288, 1 Avenue Jean Poulhes, BP 84225, 31432 Toulouse cedex 4, France; INI-CRCT F-CRIN, GREAT Networks, France
4 shared publications François Koukoui
Inserm U1048, équipe 7, obésité et insuffisance cardiaque : approches moléculaires et cliniques, BP 84225, 1, avenue Jean Poulhès, 31432 Toulouse Cedex 4, France
3 shared publications- Michel Galinier
Department of Cardiology, Rangueil University Hospital, Toulouse, France
3 shared publications Romain Harmancey
Inserm U1048, équipe 7, obésité et insuffisance cardiaque : approches moléculaires et cliniques, BP 84225, 1, avenue Jean Poulhès, 31432 Toulouse Cedex 4, France
3 shared publicationsCamille Dambrin
Inserm U1048, équipe 7, obésité et insuffisance cardiaque : approches moléculaires et cliniques, BP 84225, 1, avenue Jean Poulhès, 31432 Toulouse Cedex 4, France
2 shared publications
Latest Publications
- Open Access
- 1 January 2015
- Published by EDP Sciences in médecine/sciences
- Vol. 31 (1) , 31-34
APOO, une protéine mitochondriale impliquée dans la cardiomyopathie diabétique
- 1 January 2015
- Published by EDP Sciences in médecine/sciences
- Vol. 31 (1) , 31-34
Open AccessAPOO, une protéine mitochondriale impliquée dans la cardiomyopathie diabétique
- Open Access
- 14 September 2014
- Published by Springer Nature in BMC Systems Biology
- Vol. 8 (1) , 109
13C metabolic flux analysis shows that resistin impairs the metabolic response to insulin in L6E9 myotubes
It has been suggested that the adipokine resistin links obesity and insulin resistance, although how resistin acts on muscle metabolism is controversial. We aimed to quantitatively analyse the effects of resistin on the glucose metabolic flux profile and on insulin response in L6E9 myotubes at the metabolic level using a tracer-based metabolomic approach and our in-house developed software, Isodyn.
- 14 September 2014
- Published by Springer Nature in BMC Systems Biology
- Vol. 8 (1) , 109
Open Access13C metabolic flux analysis shows that resistin impairs the metabolic response to insulin in L6E9 myotubes
It has been suggested that the adipokine resistin links obesity and insulin resistance, although how resistin acts on muscle metabolism is controversial. We aimed to quantitatively analyse the effects of resistin on the glucose metabolic flux profile and on insulin response in L6E9 myotubes at the metabolic level using a tracer-based metabolomic approach and our in-house developed software, Isodyn.
- Open Access
- 17 April 2014
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 124 (5) , 2277-2286
Apolipoprotein O is mitochondrial and promotes lipotoxicity in heart
Diabetic cardiomyopathy is a secondary complication of diabetes with an unclear etiology. Based on a functional genomic evaluation of obesity-associated cardiac gene expression, we previously identified and cloned the gene encoding apolipoprotein O (APOO), which is overexpressed in hearts from diabetic patients. Here, we generated APOO-Tg mice, transgenic mouse lines that expresses physiological levels of human APOO in heart tissue. APOO-Tg mice fed a high-fat diet exhibited depressed ventricular function with reduced fractional shortening and ejection fraction, and myocardial sections from APOO-Tg mice revealed mitochondrial degenerative changes. In vivo fluorescent labeling and subcellular fractionation revealed that APOO localizes with mitochondria. Furthermore, APOO enhanced mitochondrial uncoupling and respiration, both of which were reduced by deletion of the N-terminus and by targeted knockdown of APOO. Consequently, fatty acid metabolism and ROS production were enhanced, leading to increased AMPK phosphorylation and Ppara and Pgc1a expression. Finally, we demonstrated that the APOO-induced cascade of events generates a mitochondrial metabolic sink whereby accumulation of lipotoxic byproducts leads to lipoapoptosis, loss of cardiac cells, and cardiomyopathy, mimicking the diabetic heart–associated metabolic phenotypes. Our data suggest that APOO represents a link between impaired mitochondrial function and cardiomyopathy onset, and targeting APOO-dependent metabolic remodeling has potential as a strategy to adjust heart metabolism and protect the myocardium from impaired contractility.
- 17 April 2014
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 124 (5) , 2277-2286
Open AccessApolipoprotein O is mitochondrial and promotes lipotoxicity in heart
Diabetic cardiomyopathy is a secondary complication of diabetes with an unclear etiology. Based on a functional genomic evaluation of obesity-associated cardiac gene expression, we previously identified and cloned the gene encoding apolipoprotein O (APOO), which is overexpressed in hearts from diabetic patients. Here, we generated APOO-Tg mice, transgenic mouse lines that expresses physiological levels of human APOO in heart tissue. APOO-Tg mice fed a high-fat diet exhibited depressed ventricular function with reduced fractional shortening and ejection fraction, and myocardial sections from APOO-Tg mice revealed mitochondrial degenerative changes. In vivo fluorescent labeling and subcellular fractionation revealed that APOO localizes with mitochondria. Furthermore, APOO enhanced mitochondrial uncoupling and respiration, both of which were reduced by deletion of the N-terminus and by targeted knockdown of APOO. Consequently, fatty acid metabolism and ROS production were enhanced, leading to increased AMPK phosphorylation and Ppara and Pgc1a expression. Finally, we demonstrated that the APOO-induced cascade of events generates a mitochondrial metabolic sink whereby accumulation of lipotoxic byproducts leads to lipoapoptosis, loss of cardiac cells, and cardiomyopathy, mimicking the diabetic heart–associated metabolic phenotypes. Our data suggest that APOO represents a link between impaired mitochondrial function and cardiomyopathy onset, and targeting APOO-dependent metabolic remodeling has potential as a strategy to adjust heart metabolism and protect the myocardium from impaired contractility.
- Open Access
- 24 June 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6) , e20414
Blood Signature of Pre-Heart Failure: A Microarrays Study
The preclinical stage of systolic heart failure (HF), known as asymptomatic left ventricular dysfunction (ALVD), is diagnosed only by echocardiography, frequent in the general population and leads to a high risk of developing severe HF. Large scale screening for ALVD is a difficult task and represents a major unmet clinical challenge that requires the determination of ALVD biomarkers. 294 individuals were screened by echocardiography. We identified 9 ALVD cases out of 128 subjects with cardiovascular risk factors. White blood cell gene expression profiling was performed using pangenomic microarrays. Data were analyzed using principal component analysis (PCA) and Significant Analysis of Microarrays (SAM). To build an ALVD classifier model, we used the nearest centroid classification method (NCCM) with the ClaNC software package. Classification performance was determined using the leave-one-out cross-validation method. Blood transcriptome analysis provided a specific molecular signature for ALVD which defined a model based on 7 genes capable of discriminating ALVD cases. Analysis of an ALVD patients validation group demonstrated that these genes are accurate diagnostic predictors for ALVD with 87% accuracy and 100% precision. Furthermore, Receiver Operating Characteristic curves of expression levels confirmed that 6 out of 7 genes discriminate for left ventricular dysfunction classification. These targets could serve to enhance the ability to efficiently detect ALVD by general care practitioners to facilitate preemptive initiation of medical treatment preventing the development of HF.
- 24 June 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (6) , e20414
Open AccessBlood Signature of Pre-Heart Failure: A Microarrays Study
The preclinical stage of systolic heart failure (HF), known as asymptomatic left ventricular dysfunction (ALVD), is diagnosed only by echocardiography, frequent in the general population and leads to a high risk of developing severe HF. Large scale screening for ALVD is a difficult task and represents a major unmet clinical challenge that requires the determination of ALVD biomarkers. 294 individuals were screened by echocardiography. We identified 9 ALVD cases out of 128 subjects with cardiovascular risk factors. White blood cell gene expression profiling was performed using pangenomic microarrays. Data were analyzed using principal component analysis (PCA) and Significant Analysis of Microarrays (SAM). To build an ALVD classifier model, we used the nearest centroid classification method (NCCM) with the ClaNC software package. Classification performance was determined using the leave-one-out cross-validation method. Blood transcriptome analysis provided a specific molecular signature for ALVD which defined a model based on 7 genes capable of discriminating ALVD cases. Analysis of an ALVD patients validation group demonstrated that these genes are accurate diagnostic predictors for ALVD with 87% accuracy and 100% precision. Furthermore, Receiver Operating Characteristic curves of expression levels confirmed that 6 out of 7 genes discriminate for left ventricular dysfunction classification. These targets could serve to enhance the ability to efficiently detect ALVD by general care practitioners to facilitate preemptive initiation of medical treatment preventing the development of HF.